Bug-drug mismatch software for hospitals, the alerting tools compared and how to catch a mismatch earlier
Most US stewardship platforms flag a bug-drug mismatch once the susceptibility result posts. Here is which products do it, what published hospitals found when they switched the alert on, and how to cut the number of mismatches before the culture comes back.
8 min read
Bug-drug mismatch software watches two feeds at once, the microbiology results and the medication administration record, and alerts a pharmacist when a patient is on an antibiotic the organism tests resistant to. In the US it is sold as one rule inside a clinical surveillance platform (Sentri7, TheraDoc, Inovalon Pharmacy Surveillance, BD HealthSight, ICNet) or built in the EHR's own stewardship module. No vendor publishes a price.
The alert works after the culture result is back, usually two to three days into therapy. The other half of the problem is the empiric choice made on day one, and that is where the hospital antibiogram does the work. This comparison covers both, and it is written for the pharmacy director or stewardship lead deciding what to buy.
What bug-drug mismatch software actually checks
Public Health Ontario's stewardship guidance defines a bug-drug mismatch as a situation in which the antimicrobials a patient is receiving do not provide adequate therapy for the organism presumed to be causing the infection, for example because the organism is resistant. The rule in software is simpler than that. When a susceptibility result is verified, the system compares each reported R against the antibiotics on the active medication list and puts a card on the pharmacist's worklist when they match.
Three inputs have to be clean for that to work: a live lab interface carrying organism and susceptibility results, a medication feed that knows what is actually being given, and a rule set that knows which drugs cover which organisms, including intrinsic resistance. That is why the rule almost always lives in a surveillance platform or the EHR rather than in a stand-alone tool.
Bug-drug mismatch software options compared
How the three biggest platforms differ beyond this one rule is covered in Sentri7 vs TheraDoc vs VigiLanz, and the Epic route in Epic antimicrobial stewardship module vs third-party tools.
| Product | How it handles mismatches | Where it runs | Price |
|---|---|---|---|
| Sentri7 Pharmacy (Wolters Kluwer) | Monitors bug-drug mismatches and antibiotics without a positive culture | Separate platform fed by EHR and lab interfaces | Quoted |
| TheraDoc (Premier) | Alerts for de-escalation and bug-drug mismatches | Separate platform with an EHR connection | Quoted |
| Inovalon Pharmacy Surveillance (former VigiLanz) | Near real-time alerts for drug-bug mismatches and duplicate therapy | Separate platform, cloud | Quoted |
| Epic antimicrobial stewardship module | Configurable rule built by your Epic analysts | Inside Epic | Part of the Epic contract plus build hours |
| BD HealthSight Clinical Advisor | Flags an antibiotic that is likely ineffective for the diagnosed infection | Separate platform | Quoted |
| ICNet (Baxter) | Drug-bug mismatch, bug-no-drug and drug-no-bug alerts | Separate platform | Quoted |
| Antimicrobe | No alerts. Ranks empiric options by your own susceptibility rates | Browser, from a lab export | $249 a month, Lab plan |
The products one by one
Sentri7 is the most widely cited. Wolters Kluwer describes it as cutting antimicrobial cost by monitoring bug-drug mismatches and patients on antibiotics without a positive culture. A community hospital that published its Sentri7 results (Smith and colleagues, Hospital Pharmacy, 2014) defined the rule as "organism isolated is resistant to antibiotic prescribed" and logged 21 mismatch interventions in 2012, all accepted, out of 2,003 stewardship interventions that year.
TheraDoc, sold by Premier, lists alerts to de-escalate therapy and notify of bug-drug mismatches in Premier's own description of the product. VigiLanz is now part of Inovalon, whose pharmacy surveillance product describes near real-time alerts for drug-bug mismatches and duplicate therapies. BD markets HealthSight Clinical Advisor with stewardship alerts in the pharmacy workflow for an antibiotic that is inappropriate for the patient's infection. ICNet, owned by Baxter, groups the rule with bug-no-drug and drug-no-bug alerts.
Epic hospitals often build the rule themselves. Stanford described its Epic stewardship build in Open Forum Infectious Diseases in 2016 (Mui and colleagues): rules for restricted drugs and bug-drug mismatch, among others, cut daily review time from 41 to 14 hours and time to appropriate therapy for E. faecium bacteremia from 18 to 9 hours. The University of Chicago reported a similar Epic build in 2017. Oracle Health and MEDITECH sell stewardship worklists and surveillance, but neither product page we found names a mismatch rule, so ask for a demo of it specifically.
How many mismatch alerts are worth acting on?
About half, in the best published US look at it. Pharmacists at AtlantiCare in New Jersey reviewed 105 mismatch alerts from August 2019 to March 2020 and acted on 48 of them, 45.7 percent (Whittaker and colleagues, OFID 2020). The rest were contamination, colonization or not appropriate to act on.
The source of the culture matters most. Blood culture alerts led to an intervention 64 percent of the time and wound cultures 56 percent. Urine alerts led to one only 24 percent of the time, and they were the largest group, 51 of the 105. A hospital that turns the rule on for every specimen will spend most of its alert time on urine cultures that are often colonization.
- Start with blood and sterile site cultures, then add wounds and respiratory specimens
- Suppress alerts for organisms the rule set treats as likely contaminants unless repeated
- Check how the rule handles intrinsic resistance and cascade-suppressed results before go-live
- Count accepted interventions per alert, not alerts fired, when you report the rule to the committee
Is bug-drug mismatch software worth it for a small hospital?
Only if someone is on shift to act on the alerts. A mismatch alert is useful in the hours after a result posts, and a stewardship program with one pharmacist working a few hours a week will see most alerts after the prescriber has already changed the drug. In a 2019 AJIC study of MDRO cases in a large medical group, prescribers corrected most mismatches on their own once the result was back.
For a hospital under about 200 beds, the order that usually pays off is the antibiogram and empiric guidance first, then alerting once there is pharmacist coverage to respond. Hospitals already on Epic, MEDITECH or Oracle Health should price the EHR's own stewardship worklist before a separate platform.
Rolling the rule out also means training the night and weekend pharmacists on which alerts to act on and which to close, and a corporate training platform keeps that training and its sign-offs in one place when staff turn over.
Small hospital options are compared in best antimicrobial stewardship software for community hospitals.
How much does bug-drug mismatch software cost?
No vendor in this category publishes a price. Sentri7, TheraDoc, Inovalon, BD and ICNet are quoted per organization, usually with an implementation fee and the interface work on the hospital's side. Per-bed figures that circulate online come from unsourced listicles, so treat them as guesses until you have a quote.
In an EHR module the license is often already paid, and the cost is analyst build time, testing and rule maintenance. Ask for the first-year total including interfaces, and ask how many pharmacist hours a week the vendor's reference sites spend clearing the worklist.
Antibiogram costs by route, including EHR build hours, are in antibiogram software cost.
Catching the mismatch before the culture comes back
A mismatch alert fixes the drug on day two or three. The larger number is set on day one. In 131 US hospitals, 19 percent of 21,608 patients with a bloodstream infection got empiric therapy their organism was not susceptible to, and those patients had higher odds of death, an adjusted odds ratio of 1.46 (Kadri and colleagues, Lancet Infectious Diseases, 2021). A resistant organism was the strongest predictor of that discordance.
Empiric choices are only as good as the local susceptibility data behind them. That is the job of the cumulative antibiogram, cut by unit and specimen source so the ICU prescriber is not reading a house-wide number that flatters the ICU. Antimicrobe builds that antibiogram from your lab's susceptibility export, applies the CLSI M39 first isolate and 30 isolate rules, and ranks empiric options for each organism group by your own rates.
It does not send alerts, read the medication record or document interventions. It sits upstream of a mismatch rule and makes fewer mismatches for the rule to catch. The Lab plan is $249 a month for one facility, bought by card, and Stewardship at $749 a month adds unit cuts, syndrome groups, quarterly trends and MDRO counts.
How the ranking works is on empiric antibiotic therapy by your antibiogram, unit tables on ICU antibiogram software, and the full report on hospital antibiogram software.
Questions to ask in a bug-drug mismatch software demo
- Show me the mismatch rule firing on a real result. Which susceptibility status triggers it, and is it the released result or the instrument result?
- How does the rule treat intrinsic resistance, suppressed antibiotics and polymicrobial cultures?
- Can we limit the rule by specimen source, starting with blood?
- What share of mismatch alerts lead to an intervention at your reference sites?
- Which other alerts arrive on the same worklist, and how is it prioritized?
- What is the first-year cost including interfaces and implementation?
Related on this site: pharmacy surveillance software, Sentri7 vs TheraDoc vs VigiLanz, Sentri7 alternatives, Epic antimicrobial stewardship module, empiric antibiotic therapy.